Professional Designation Chief surgeon
Department  Thoracic Surgery
Organization of Employment Shanghai Chest Hospital, Jiaotong University Medical School
Degrees MD

Profile

Dr. Fang is currently Professor and Chief surgeon of Thoracic Surgery and of Respiratory Surgery at Shanghai Chest Hospital and Honorary Chair of Mediastinal Tumor Committee of Chinese Anti-Cancer Association, China. He is a member of IASLC, serving at the Staging and Prognostic Factor Committee and the Multidisciplinary Clinical Science Committee. He is also a member of the AATS, and committee member at the EACTS and the ASCVTS thoracic domain.

Dr. Fang has a full range of practice in surgical management of pulmonary, mediastinal, and esophageal diseases. His expertise lies mainly in minimally invasive surgery and multimodality treatment of thoracic oncology, including lung cancers, esophageal cancers, and mediastinal tumors. 

His research interests focus on surgery in the multidisciplinary treatment of thoracic malignancies, particularly innovation in surgery and treatment modalities, disease mechanisms, and development of novel drugs. 

Dr. Fang has also been actively involved in educational activities, including acting as the director for resident and fellowship programs as well as the Royal College of Surgeons advanced VATS training program at the Shanghai Chest Hospital.

Recent & Current Appointments and Committee Memberships

  • Honorary Chair of Mediastinal Tumor Committee of Chinese Anti-Cancer Association, China.
  • Member of IASLC, serving at the Staging and Prognostic Factor Committee and the Multidisciplinary Clinical Science Committee. 
  • Member of the AATS
  • Committee member at the EACTS and the ASCVTS thoracic domain.

Research Interests

Surgery-oriented multi-disciplinary treatment of thoracic oncology, focusing on innovation in surgery and treatment models, disease mechanism studies, and development of novel drugs.

IASLC Naruke Lectureship Award 2024

  • 2024, Xiuxiu Hao, Zhitao Gu, Haoran Liu, Xuefei Zhang, Ning Xu, Teng Mao, Wentao Fang. Internal jugular vein pressure monitoring guided venous reconstruction could improve perioperative safety after superior vena cava resection for mediastinal tumors: a cohort study. International J Surg. (IF: 15.4; Corresponding author)
  • 2023, Fang W, Girard N, Cilento V, et al. The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: Proposals for the N and the M Components for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors. J Thorac Oncol. (IF: 20.4; first author)
  • 2023, Ugalde Figueroa P, Marques E, Cilento VJ, Fang W, et al. Completeness of Resection and Long-Term Survival of Patients Undergoing Resection for Pathologic T3 NSCLC: An International Association for the Study of Lung Cancer Analysis. J Thorac Oncol. (IF: 20.4; Last author)
  • 2023, Gu Z, Hao X, Liu Y, Fang W, et al. Minimally Invasive Thymectomy Could Be Attempted for Locally Advanced Thymic Malignancies: A Real-World Study With Propensity Score-Matched Analysis. J Thorac Oncol. (IF: 20.4; corresponding author)
  • 2023, Guo X, Wang Z, Yang H, Fang W, et al. Impact of Lymph Node Dissection on Survival After Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: From the Results of NEOCRTEC5010, a Randomized Multicenter Study. Ann Surg. (IF: 10.1; corresponding author)

  • KC1036 as a second or later line treatment for recurrent/metastatic thymic carcinoma: a multicenter prospective single-arm phase II trial. CTR20223423
  • Biomarker informed neoadjuvant therapy for locally advanced NSCLC: a prospective umbrella design phase II trial (the PURPOSE Trial). ChiCTR2100053021
  • Minimally invasive segmentectomy versus lobectomy for stage IA GGO-containing lung adenocarcinoma: a phase III multicenter prospective controlled randomized trial (the GREAT Trial). SHDC2020CR1023B
  • KN046 as a second or later line treatment for recurrent/metastatic thymic carcinoma: a multicenter prospective single-arm phase II trial. NCT04469725
  • Sequential neoadjuvant chemoradiation for potentially unresectable thymic carcinoma: a prospective single arm phase II trial. ChiCTR-OIC-16009130